Oral cabazitaxel not checked

Jina Pharmaceuticals Inc. · 50 mg cabazitaxel · 100 mg cabazitaxel

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
4 in total · 3 in the EU
Targets
—
None known yet

What this is

How it works
Taxane chemotherapy: stops cancer cells from dividing.-taxel: taxane derivatives WHO name stem
How it’s given
“200 mg cabazitaxel to be taken every 3-week for 6 cycles (1 dose per cycle), 10 mg prednisone to be taken daily till end of cycle 6”In the company’s words, NCT06890832 on ClinicalTrials.gov
Tested for
Metastatic Castration-resistant Prostate Cancer, MCRPC
Main trialPhase 2
“A total of 75 participants will be enrolled in the study, with 25 participants allocated per intervention group. In Group 1, participant will take 50 mg cabazitaxel every week for 6 cycles (3 doses per cycle), 10 mg prednisone daily till the end of cycle 6. In Group 2, participant will take 100 mg cabazitaxel every week for 6 cycles (3 doses per cycle), 10 mg prednisone daily till the end of cycle 6. In Group 3, participant will take 200 mg cabazitaxel every 3 weeks for 6 cycles (1 doses per cycle), 10 mg prednisone daily till the end of cycle 6. The study comprises three phases: a 21-day…”In the company’s words, NCT06890832 on ClinicalTrials.gov
Other names
50 mg cabazitaxel · 100 mg cabazitaxel · 200 mg cabazitaxel

Other drugs for Metastatic Castration-resistant Prostate Cancer, MCRPC

All 193 drugs for Metastatic Castration-resistant Prostate Cancer, MCRPC

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting Dec 2026 A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer
Phase 2Ended not given A Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resistant Prostate Cancer
Phase 3Authorised not given Metastasis-directed therapy in oligoprogressive castration-refractory prostate cancer: a randomized phase 3 trial
Phase 3Authorised not given PEACE2 : A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Oral cabazitaxel

Following is part of Solo: you see every change to Oral cabazitaxel the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in